PRODIG (Prevention of new onset diabetes after transplantation by a short term treatment of Vildagliptin in the early renal post-transplant period) study: study protocol for a randomized controlled study

Abstract : Post-transplant diabetes is a frequent and serious complication of kidney transplantation. There is currently no treatment to prevent or delay the disease. Nevertheless, identification of risk factors make it possible to target a population at risk of developing de novo diabetes. We hypothesized that a short-term treatment with vildagliptin may prevent new onset diabetes after transplantation (NODAT) in high-risk patients.
Document type :
Journal articles
Complete list of metadatas

https://hal.univ-brest.fr/hal-02264845
Contributor : Geneviève Michel <>
Submitted on : Wednesday, August 7, 2019 - 4:28:37 PM
Last modification on : Saturday, August 10, 2019 - 1:11:43 AM

Links full text

Identifiers

Citation

D Gaiffe, D Crepin, D Bamoulid, D Courivaud, D Büchler, et al.. PRODIG (Prevention of new onset diabetes after transplantation by a short term treatment of Vildagliptin in the early renal post-transplant period) study: study protocol for a randomized controlled study. Trials, BioMed Central, 2019, 20 (1), pp.375. ⟨10.1186/s13063-019-3392-6⟩. ⟨hal-02264845⟩

Share

Metrics

Record views

36